Table 1: Examples of some the clinical PET biodistribution studies performed with radiolabelled anticancer agents.

DrugReferences

5-Fluorouracil[10, 11]
Temozolomide[12, 13]
N-[(2′-dimethylamino)ethyl]acridine-4-carboxamide (XR5000)[14, 15]
Antisense oligonucleotide to Survivin (LY2181308)[16, 17]
Docetaxel[18]
Paclitaxel[19]
Lapatinib[20]
Erlotinib[2123]
Anti-CD44v6 chimeric monoclonal antibody, U36[24]
Trastuzumab[25, 26]
Some radiolabelled molecular entities under evaluation in ongoing imaging studies (NIH trial database)
89Zr-Bevacizumab, 89Zr-RO5323441 (placental growth factor antibody), 18F-SKI-249380 (dasatinib derivative), 124I-PUH71, MMOT0530A (a monoclonal antibody), 18F-Paclitaxel, 11C-Erlotinib, and 89Zr-Cetuximab